| pubmed-article:21114621 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21114621 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21114621 | lifeskim:mentions | umls-concept:C0684275 | lld:lifeskim |
| pubmed-article:21114621 | lifeskim:mentions | umls-concept:C0003440 | lld:lifeskim |
| pubmed-article:21114621 | lifeskim:mentions | umls-concept:C0534191 | lld:lifeskim |
| pubmed-article:21114621 | lifeskim:mentions | umls-concept:C0015505 | lld:lifeskim |
| pubmed-article:21114621 | lifeskim:mentions | umls-concept:C0013125 | lld:lifeskim |
| pubmed-article:21114621 | lifeskim:mentions | umls-concept:C1552302 | lld:lifeskim |
| pubmed-article:21114621 | lifeskim:mentions | umls-concept:C1552291 | lld:lifeskim |
| pubmed-article:21114621 | lifeskim:mentions | umls-concept:C0522503 | lld:lifeskim |
| pubmed-article:21114621 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:21114621 | pubmed:dateCreated | 2011-1-28 | lld:pubmed |
| pubmed-article:21114621 | pubmed:abstractText | OBJECTIVE: The objective of the present study was to evaluate the pharmacokinetics and the clearance pathways of rFVIIa after intravenous administration to hemophilia patients. METHODS: Ten severe hemophilia patients were included in the study; all patients were intravenously administered a clinically relevant dose of 90 ?g kg(-1) (1.8 nmol kg(-1)) rFVIIa. Blood samples were collected consecutively to describe the pharmacokinetics of rFVIIa. All samples were analyzed using three different assays: a clot assay to measure the activity (FVIIa:C), an enzyme immunoassay (EIA) to measure the antigen levels (FVII:Ag), and an EIA (FVIIa-AT) to measure the FVIIa antithrombin III (AT) complex. Pharmacokinetic parameters were evaluated both by use of standard non-compartmental methods and by use of mixed effects methods. A population pharmacokinetic model was used to simultaneously model all three datasets. The total body clearance of rFVIIa:C was estimated to be 38 mL h(-1) kg(-1). The rFVII-AT complex formation was responsible for 65% of the total rFVIIa:C clearance. The initial and the terminal half-life of rFVIIa:C was estimated to be 0.6 and 2.6 h, respectively. The formation of rFVII-AT complex was able to explain the difference observed between the rFVIIa:C and the rFVII:Ag concentration. The non-compartmental analysis resulted in almost identical parameters. | lld:pubmed |
| pubmed-article:21114621 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21114621 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21114621 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21114621 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21114621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21114621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21114621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21114621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21114621 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21114621 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:21114621 | pubmed:issn | 1538-7836 | lld:pubmed |
| pubmed-article:21114621 | pubmed:author | pubmed-author:HednerUU | lld:pubmed |
| pubmed-article:21114621 | pubmed:author | pubmed-author:MartinE JEJ | lld:pubmed |
| pubmed-article:21114621 | pubmed:author | pubmed-author:EzbanMM | lld:pubmed |
| pubmed-article:21114621 | pubmed:author | pubmed-author:CarrMM | lld:pubmed |
| pubmed-article:21114621 | pubmed:author | pubmed-author:PelzerHH | lld:pubmed |
| pubmed-article:21114621 | pubmed:author | pubmed-author:BrophyD FDF | lld:pubmed |
| pubmed-article:21114621 | pubmed:author | pubmed-author:AgersøHH | lld:pubmed |
| pubmed-article:21114621 | pubmed:copyrightInfo | © 2011 International Society on Thrombosis and Haemostasis. | lld:pubmed |
| pubmed-article:21114621 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21114621 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:21114621 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21114621 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21114621 | pubmed:pagination | 333-8 | lld:pubmed |
| pubmed-article:21114621 | pubmed:meshHeading | pubmed-meshheading:21114621... | lld:pubmed |
| pubmed-article:21114621 | pubmed:meshHeading | pubmed-meshheading:21114621... | lld:pubmed |
| pubmed-article:21114621 | pubmed:meshHeading | pubmed-meshheading:21114621... | lld:pubmed |
| pubmed-article:21114621 | pubmed:meshHeading | pubmed-meshheading:21114621... | lld:pubmed |
| pubmed-article:21114621 | pubmed:meshHeading | pubmed-meshheading:21114621... | lld:pubmed |
| pubmed-article:21114621 | pubmed:meshHeading | pubmed-meshheading:21114621... | lld:pubmed |
| pubmed-article:21114621 | pubmed:meshHeading | pubmed-meshheading:21114621... | lld:pubmed |
| pubmed-article:21114621 | pubmed:meshHeading | pubmed-meshheading:21114621... | lld:pubmed |
| pubmed-article:21114621 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21114621 | pubmed:articleTitle | Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients. | lld:pubmed |
| pubmed-article:21114621 | pubmed:affiliation | Pharmacology, Biopharmaceuticals Research Unit, Novo Nordisk A/S, Maaloev, Denmark. hkag@novonordisk.com | lld:pubmed |
| pubmed-article:21114621 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21114621 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21114621 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
